SBIR Phase I: Continuous Manufacturing for Nucleic Acid Lipid Nanoparticles to Improve the — NSF Award to DIANT PHARMA INC. (CT, $
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project addresses the need for advanced manufacturing technology that can produce future therapeutics and vaccines. Future clinical treatments will rely on continuous manufacturing to meet demand, both with respect to vol
| Award title | SBIR Phase I: Continuous Manufacturing for Nucleic Acid Lipid Nanoparticles to Improve the |
|---|---|
| Award ID | 2151477 |
| Awardee | DIANT PHARMA INC. |
| City | MANCHESTER |
| State | CT |
| Amount obligated | $256,000 |
| Principal investigator | Antonio Costa |
| Program | SBIR Phase I |
| Start date | 02/15/2022 |
| Abstract | The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project addresses the need for advanced manufacturing technology that can produce future therapeutics and vaccines. Future clinical treatments will rely on continuous manufacturing to meet demand, both with respect to volume and drug product personalization. This project will incorporate continuous manufacturing principles and process analytical sensors and technology. These processes will enable f |
| Source | NSF Awards |
$799/mo
Try NSFGrants →